(A) Further development is based on: * >60% of patients being single or f †30% of patients being multi-TUMAP responders. (B) The number of vaccine-induced TUMAP responses is shown for the overall immune evaluable patient population (n=40) as well as for study cohorts. Black lines indicate mean values. For statistical analysis the Mann-Whitney test was used.
Abbreviations: HBV, hepatitis B virus-derived vaccinated marker peptide; TUMAP, tumor associated peptide; VI, vaccine induced.